Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439146 | 1.00 | PPARG (0.58) | PPARGHSD17B2HSD17B1PPARA | |
| SCHEMBL2859545 | 0.92 | PPARG (0.61) | PPARGHSD17B2HSD17B1 | |
| SCHEMBL3439044 | 0.82 | HSD17B2 (0.58) | HSD17B2HSD17B1 | |
| SCHEMBL2851697 | 0.82 | HSD17B2 (0.58) | HSD17B2HSD17B1 | |
| SCHEMBL2847856 | 0.82 | HSD17B2 (0.58) | HSD17B2HSD17B1 | |
| SCHEMBL6183482 | 0.81 | HSD17B2 (0.60) | HSD17B2HSD17B1 | |
| SCHEMBL2849845 | 0.81 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL2849821 | 0.81 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL2847849 | 0.81 | PPARG (0.58) | PPARGPPARA | |
| SCHEMBL2847851 | 0.81 | PPARG (0.58) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807669-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARA, PPARD | PPARG 1/4885HSD17B2 448/4885HSD17B1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.